Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders - Seite 4

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact [e-mail]

References
[1] Lancet 2016; 388: 2239-53 Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

# # #

Novartis Media Relations
Central media line: [phone]
E-mail: [e-mail]

Eric Althoff Novartis Global Media Relations [phone] (direct) [phone] (mobile) [e-mail]

Agnes Estes Novartis Global Pharma Communications [phone] (direct) [phone] (mobile) [e-mail]

Novartis Investor Relations
Central investor relations line: [phone]
E-mail: [e-mail]

Central		North America
Samir Shah	[phone]	Richard Pulik	[phone]
Pierre-Michel Bringer	[phone]	Sloan Pavsner	[phone]
Thomas Hungerbuehler	[phone]
Isabella Zinck	[phone]